Moises Martínez-Castillo, Experimental Medicine Research Unit, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México
Itzel Altamirano-Mendoza, Experimental Medicine Research Unit, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM); Research Directorate, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes; Ciudad de México, México
Benjamín León-Mancilla, Experimental Medicine Research Unit, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM);; Department of Surgery, Faculty of Medicine, UNAM; Ciudad de México, México
Daniel Santana-Vargas, Experimental Medicine Research Unit, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México
Erik García-Cervantes, Department of Gynecology and Obstetrics, Hospital General de México “Dr. Eduardo Liceaga”, Ciudad de México, México
Rocio Guerrero-Bustos, Department of Gynecology and Obstetrics, Hospital General de México “Dr. Eduardo Liceaga”, Ciudad de México, México
Gabriela Gutiérrez-Reyes, Experimental Medicine Research Unit, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México
Objective: To assess the pluripotency profile of human mesenchymal stem cells (hMSCs) as influenced by delivery mode and obstetric-gynecological background. Methods: Thirty-nine placentas were included. A fragment of the AM (5 cm) was utilized to obtain the AM-hMSCs. The cell cultures were monitored until 90% confluence, before carrying out expansion (passages). The cultures, cell morphology, adhesion, immunophenotyping characterization, and differentiation capacity were evaluated and compared with hMSC from bone marrow (BM-hMSC). T-student and Mann-Whitney U tests were carried out. Statistical significance was set at a p < 0.05. Results: No differences were observed in the proliferation and expansion of AM-hMSC obtained by vaginal or cesarean delivery route. Similar results were observed in the immunological characterization; however, CD105 was significantly lower compared with BM-hMSC. Nevertheless, cells from vaginal or cesarean delivery route showed great differentiation capacity to adipogenic, chondrogenic, and osteogenic lineages. Conclusions: The delivery route, clinical data, and obstetric and gynecologic histories are no limitations for using the AM to obtain hMSC and its possible application in Regenerative Medicine.
Keywords: Delivery route. Obstetric history. Mesenchymal stem cells. Amniotic membrane. Immunophenotyping. Cell differentiation.